


Financial tear sheet

Corporate Profile

2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.

Stock Information

BAX (BAX)	
Exchange	NYSE (US Dollar)
Price	\$60.87
Change (%)	▲ 0.05 (0.08%)
Volume	2,308,236
52 Week Low	\$43.13
Market Cap	\$33,166,292,535
Rolling EPS	1.64
PE Ratio	37.0946
Shares Outstanding	544,870,914
Data as of 08/18/2017 4:01 PM ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

DATE	TITLE
08/15/17	Baxter to Present at the Goldman Sachs 14th Annual European Medtech and Healthcare Services Conference
07/27/17	Baxter Completes Acquisition of Claris Injectables, Expanding Generic Injectable Medicines Portfolio
07/26/17	Baxter Reports Second-Quarter 2017 Results and Provides Updated Financial Outlook for 2017 and 2020

Recent & Upcoming Events

DATE	TITLE
07/26/2017 7:30 AM CT	Q2 2017 Baxter International Inc. Earnings Conference Call
09/06/2017 7:45 AM CT	Goldman Sachs 14th Annual European Medtech and Healthcare Services Conference

SEC Filings

FILING DATE	FORM
08/18/17	4
08/07/17	10-Q
07/26/17	3
07/26/17	4

Primary IR Contact

Clare Trachtman
Baxter International Inc.
Phone: 224-948-3085